Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Sep 2019: Trial registered, NCT04083170
  2. 6 Oct 2022: Trial started, NCT04083170
  3. 30 Nov 2022: Trial terminated, NCT04083170
  4. 1 Jan 2025: Trial results posted, NCT04083170

The trials

NCT04083170: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

State
Stopped early
Phase
Phase 2
People
1 taking part
Started
6 Oct 2022
Primary completion
11 Nov 2022
Arms
Regimen A (fludarabine, cyclophosphamide, TBI, dilanubcel)
Results
Posted on the registry
  1. 10 Sep 2019: Trial registered
  2. 6 Oct 2022: Trial started
  3. 30 Nov 2022: Trial terminated
  4. 1 Jan 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.